• 1
    Barker DJP, Osmond C, Golding J, Kuth D, Wadsworth MEJ. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 1989; 298: 5647.
  • 2
    Law CM, de Swiet M, Osmond C et al. Initiation of hypertension in utero and its amplification throughout life. BMJ 1993; 306: 2427.
  • 3
    Hales CN, Barker DJP, Clark PMS et al. Fetal and infant growth and impaired glucose tolerance at age 64 years. BMJ 1991; 303: 101922.
  • 4
    Simmons RA, Tempelkton LJ, Gertz SJ. Intrauterine growth retardation leads to the development of type 2 diabetes in the rat. Diabetes 2001; 50: 227986.
  • 5
    Phillips DIW, Barker DJP, Hales CN, Hirst S, Osmond C. Thinness at birth and insulin resistance in adult life. Diabetologia 1994; 37: 1504.
  • 6
    Reaven GM. Role of insulin resistance in human disease. Diabetes 1998; 37: 1595607.
  • 7
    Kistner A, Celsi G, Vanpee M, Jacobson SH. Increased blood pressure but normal renal function in adult women born preterm. Pediatr Nephrol 2000; 15: 21520.
  • 8
    Barker DJP, Osmond C, Simmonds SJ, Wield GA. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life. BMJ 1993; 306: 4226.
  • 9
    Martyn CN, Barker DJP, Osmond C. Mothers’ pelvic size, fetal growth, and death from stroke and coronary heart disease in men in the UK. Lancet 1996; 348: 12648.
  • 10
    Oliver MH, Harding JE, Breier BH, Evans PC, Gluckman PD. Glucose but not a mixed amino acid infusion regulates plasma insulin-like growth factors-I concentrations in fetal sheep. Pediatr Res 1993; 34: 6265.
  • 11
    Bang P, Hall K. IGFs as endocrine, and paracrine hormones. In: SchofieldPN, ed. The Insulin-Growth Factors: Structure and Biological Function. Oxford: Oxford University Press, 1992; 15177.
  • 12
    Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002; 359: 17405.
  • 13
    Lee PD, Giudice LC, Conover CA, Powell DR. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc Soc Exp Biol Med 1997; 216: 31957.
  • 14
    Sara VR, Hall K. The insulin-like growth factors and their binding proteins. Physiol Rev 1990; 70: 591614.
  • 15
    Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 1994; 79: 8728.
  • 16
    Taylor AM, Dunger DB, Preece MA et al. The growth hormone independent insulin-like growth factor-I binding protein BP28 is associated with serum insulin-like growth factor-I inhibitory bioactivity in adolescent insulin-dependent diabetes. Clin Endocrin 1990; 32: 22939.
  • 17
    Brismar K, Grill V, Efédic S, Hall K. The insulin-like growth factor binding protein −1 in low and high insulin responders before and during dexamethasone treatment. Metabolism 1991; 40: 72832.
  • 18
    Mogul HR, Marshalö M, Frey M et al. Insulin-like growth factor binding protein-1 as a marker for hyperinsulinemia in obese postmenopausal women. J Clin Endocrinol Metab 1996; 81: 44925.
  • 19
    Grill V, Pigon J, Hartling SG, Binder C, Efendic S. Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high insulin responders. Metabolism 1990; 39: 2518.
  • 20
    Bang P, Eriksson U, Sara V, Wivall IL, Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF- I as radioligand. Acta Endocrinol (Copenh) 1991; 124: 6209.
  • 21
    Hilding A, Hall K, Wivall-Helleryd, Sääf M, Melin AL, Thorén M. Serum levels of insulin-like growth factor-1 in 152 patients with growth hormone deficiency, aged 19–82 years, in relation to those in healthy subjects. J Clin Endocrinol Metab 1998; 84: 20139.
  • 22
    Povoa G, Roovete A, Hall K. Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol 1984; 107: 56370.
  • 23
    Fernqvist-Forbes E, Hilding A, Ekberg K, Brismar K. Influence of circulating epinephrine and norepinephrine on insulin-like growth factor binding protein-1 in humans. J Clin Endocrinol Metab 1997; 82: 267780.
  • 24
    Olivecrona H, Hilding A, Ekstrom C et al. Acute and short-term effects of growth hormone on insulin-like growth factors and their binding proteins: serum levels and hepatic messenger ribonucleic acid responses in humans. J Clin Endocrinol Metab 1999; 84: 55360.
  • 25
    Brismar K, Hilding A, Lindgren B. Regulation of IGFBP-1 in humans. Prog Growth Factor Res 1995; 6: 44956.
  • 26
    Giudice LC, de Zegher F, Gargosky SE et al. Insulin-like growth factors and their binding proteins in the term and preterm fetus and neonates with normal and extremes of intrauterine growth. J Clin Endocrinol Metab 1995; 80: 154855.
  • 27
    Hong Y, Brismar K, Hall K, Pedersen NL, de Faire U. Associations between insulin-like growth factor-I (IGF-I), IGF-binding protein-1, insulin and other metabolic measures after controlling for genetic influences: results from middle-aged and elderly monozygotic twins. J Endocrinol 1997; 153: 2517.
  • 28
    Lemne C, Brismar K. Insulin-like growth factor binding protein-1 as a marker of the metabolic syndrome – a study in borderline hypertension. Blood Press 1998; 7: 8995.
  • 29
    Heald AH, Cruickshank JK, Riste LK et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001; 44: 3339.
  • 30
    Saitoh H, Kamoda T, Nakahara S, Hirano T, Matsui A. Insulin-like growth factor binding protein-1 as a predictor of glucose-stimulated hyperinsulinemia in prepubertal obese children. Eur J Endocrinol 1999; 140: 2314.
  • 31
    Clauson P, Brismar K, Hall K, Linnarsson R, Grill V. Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden. Scand J Clin Lab Invest 1998; 58: 35360.
  • 32
    Mortensen DL, Won WB, Reifsnyder D, Gironella M, Etcheverry T, Clark RG. Insulin-like growth factor binding protein −1 induces insulin release in the rat. Endocrinology 1997; 138: 207380.
  • 33
    Karlberg J, Albertsson-Wikland K. Growth in full-term small for gestational age infants: from birth to final height. Pediatr Res 1995; 38: 7339.
  • 34
    Leger J, Levy-Marchal C, Bloch J et al. Reduced final height and indications for insulin resistance in 20 year olds born small for gestational age: regional cohort study. BMJ 1997; 315: 3417.
  • 35
    Gibson JM, Aplin JD, White A, Westwood M. Regulation of IGF bioavailability in pregnancy. Mol Hum Reprod 2001; 7: 7987.
  • 36
    Hofman PL, Cutfield WS, Robinson EL et al. Insulin resistance in short children with intrauterine growth retardation. J Clin Endocrin Metab 1997; 82: 4026.
  • 37
    Jensen EC, Harding JE, Bauer MK, Gluckman PD. Metabolic effects of IGF-I in the growth retarded fetal sheep. J Endocrinol 1999; 161: 48594.
  • 38
    Lo HC, Tsao LY, Hsu WY, Chen HN, Yu WK, Chi Cy. Relation of cord serum levels of growth hormone, insulin-like growth factors, insulin-like growth factor binding proteins, leptin, and interleukin-6 with birth weight, birth length, and head circumference in term and preterm neonates. Nutrition 2002; 18: 6048.
  • 39
    Rajaram S, Carlson SE, Koo WW, Rangachari A, Kelly DP. Insulin-like growth facto (IGF-)-I and IGF-binding protein 3 during the first year in term and preterm infants. Pediatr Res 1995; 37: 5815.